Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
作者信息
Baumann Kreuziger Lisa M, Reding Mark T
机构信息
University of Minnesota, Division of Hematology, Oncology, and Transplantation, Mayo Mail Code 480, 420 Delaware St. S.E., Minneapolis, MN, 5545, USA.
出版信息
Thromb Res. 2013 Aug;132(2):e161-3. doi: 10.1016/j.thromres.2013.07.011. Epub 2013 Jul 31.
Abstract
摘要
相似文献
1
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.达比加群和利伐沙班相关出血的管理：当前实践调查
Thromb Res. 2013 Aug;132(2):e161-3. doi: 10.1016/j.thromres.2013.07.011. Epub 2013 Jul 31.
2
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.新型直接口服抗凝剂（DOACs），即阿哌沙班、达比加群和利伐沙班相关并发症的紧急处理建议。
Clin Res Cardiol. 2013 Jun;102(6):399-412. doi: 10.1007/s00392-013-0560-7. Epub 2013 May 14.
3
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].[新型口服抗凝药——华法林在房颤治疗中的落幕]
Kardiol Pol. 2012;70(10):1053-60.
4
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.达比加群、利伐沙班和华法林导致胃肠道出血的比较风险：基于人群的队列研究。
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
5
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.新型口服抗凝药达比加群和利伐沙班在皮肤外科手术中的并发症
Dermatol Surg. 2015 Jul;41(7):784-93. doi: 10.1097/DSS.0000000000000392.
6
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.特定口服抗凝剂治疗背景下出血的紧急处理的实用考虑。
Am J Emerg Med. 2014 Apr;32(4):375-82. doi: 10.1016/j.ajem.2013.11.044. Epub 2013 Dec 7.
7
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Z Gerontol Geriatr. 2012 Aug;45(6):498-504. doi: 10.1007/s00391-012-0377-4.
8
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.利伐沙班和达比加群在接受心房颤动导管消融术的患者中的应用。
Europace. 2014 Aug;16(8):1137-44. doi: 10.1093/europace/euu007. Epub 2014 Feb 18.
9
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.新型口服抗凝药不同适应症的大出血风险：来自对50项随机试验批准剂量的荟萃分析的见解
Int J Cardiol. 2015 Jan 20;179:279-87. doi: 10.1016/j.ijcard.2014.11.101. Epub 2014 Nov 13.
10
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.口服达比加群或利伐沙班患者的常规凝血筛查及抗凝强度评估：英国血液学标准委员会的指南
Br J Haematol. 2012 Nov;159(4):427-9. doi: 10.1111/bjh.12052. Epub 2012 Sep 13.
引用本文的文献
1
Diagnosis and Management of Acute Intracerebral Hemorrhage.急性脑出血的诊断与管理
Emerg Med Clin North Am. 2016 Nov;34(4):883-899. doi: 10.1016/j.emc.2016.06.010. Epub 2016 Sep 3.
2
The Influence of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation.检测方法的选择对接受利伐沙班治疗的非瓣膜性心房颤动患者凝血酶原时间测定结果的影响
J Clin Lab Anal. 2016 Nov;30(6):941-946. doi: 10.1002/jcla.21960. Epub 2016 Apr 13.
3
Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates.新型口服抗凝剂治疗的出血患者的管理：凝血酶原复合物浓缩剂的作用
Biomed Res Int. 2014;2014:583794. doi: 10.1155/2014/583794. Epub 2014 Jul 20.
4
Emergency reversal of anticoagulation: novel agents.紧急抗凝逆转：新型药物。
Curr Neurol Neurosci Rep. 2014 Aug;14(8):471. doi: 10.1007/s11910-014-0471-7.
本文引用的文献
1
Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.
J Thromb Haemost. 2013 Apr;11(4):576-8. doi: 10.1111/jth.12166.
2
Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay.使用哪种检测来测量利伐沙班的抗凝效果：抗Xa因子检测。
J Thromb Haemost. 2013 Apr;11(4):579-80. doi: 10.1111/jth.12165.
3
New anticoagulants: A concise review.新型抗凝药物：简要综述。
J Trauma Acute Care Surg. 2012 Oct;73(4):983-92. doi: 10.1097/TA.0b013e318265cf9e.
4
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.口服凝血酶和因子 Xa 抑制剂逆转的紧急指导
Am J Hematol. 2012 May;87 Suppl 1:S141-5. doi: 10.1002/ajh.23202. Epub 2012 Apr 4.
5
Does an offer for a free on-line continuing medical education (CME) activity increase physician survey response rate? A randomized trial.提供免费的在线继续医学教育（CME）活动会提高医生调查问卷的回复率吗？一项随机试验。
BMC Res Notes. 2012 Mar 7;5:129. doi: 10.1186/1756-0500-5-129.
6
How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.2012 年我如何抗凝治疗：新型抗凝药和传统抗凝药，以及何时及如何转换。
Blood. 2012 Mar 29;119(13):3016-23. doi: 10.1182/blood-2011-10-378950. Epub 2012 Feb 1.
7
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.使用HEMOCLOT直接凝血酶抑制剂测定法来测定达比加群的血浆浓度。
Blood Coagul Fibrinolysis. 2012 Mar;23(2):138-43. doi: 10.1097/MBC.0b013e32834f1b0c.
8
Assays for measuring rivaroxaban: their suitability and limitations.用于检测利伐沙班的检测方法：适用性和局限性。
Ther Drug Monit. 2010 Dec;32(6):673-9. doi: 10.1097/FTD.0b013e3181f2f264.
9
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.达比加群酯——一种新型、可逆、口服直接凝血酶抑制剂：凝血检测的解读及其抗凝活性的逆转。
Thromb Haemost. 2010 Jun;103(6):1116-27. doi: 10.1160/TH09-11-0758. Epub 2010 Mar 29.
10
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.口服直接凝血酶抑制剂和Xa因子抑制剂在研的比较药效学和药代动力学
Clin Pharmacokinet. 2009;48(1):1-22. doi: 10.2165/0003088-200948010-00001.
Zotero 插件